Eating this fatty snack every day can help you sleep better — scientists were surprised
Those delicious darlings on every brunch menu may be more than just a creamy topping.
It turns out this popular green fruit — yes, it's a fruit — may just be the key to restful slumber, according to a new study in the Journal of the American Heart Association.
Researchers tracked 969 adults aged 25 and over who had abdominal obesity, which is characterized as a waistline that is 35 inches or more for women and 40 inches or more for men.
For 26 weeks, half of the group ate one large Hass avocado per day while the other half continued their usual diet, which typically involved consuming less than two avocados per month.
As expected, the avocado-eating group saw marked improvements in their blood lipids — fatty substances like triglycerides and cholesterol — and overall diet.
But what caught researchers off guard was the fact that this trendy toast-topper also led to better sleep.
The researchers noted that avocado's impact on sleep may be due to its powerhouse blend of nutrients, as it's 'rich in monounsaturated fatty acids, dietary fiber, potassium, folate, vitamin K, copper and pantothenic acid.'
It also came as a surprise that avocado consumption was not associated with improved cardiovascular health, which was actually the original purpose of the study.
The researchers noted that avocados could benefit slumber as part of a balanced, healthy diet and should not be treated as a solitary sleep aid.
'Sleep is emerging as a key lifestyle factor in heart health, and this study invites us to consider how nutrition — and foods like avocado — can play a role in improving it,' said Dr. Kristina Petersen, study author and associate professor of nutritional sciences at Penn State University.
'Cardiovascular health is influenced by many factors, and while no single food is a silver bullet, some — like avocados — offer a range of nutrients that support multiple aspects of heart health. This is an encouraging step in expanding the science around avocados and the potential benefits of consumption.'
Other factors that can improve your sleep include cutting down on caffeine, curbing alcohol intake, kicking a smoking habit, exercising and limiting screen time before bed.
This isn't the first time the versatile superfood has made headlines for unexpected benefits.
Previous research suggests avocados may reduce 'bad' cholesterol and help with belly fat in women, thanks to their healthy fats and high fiber content.
A 2024 study suggests that eating a small amount of avocado every day may lower a woman's risk for Type 2 diabetes.
Just make sure not to overdo it.
Experts generally recommend eating no more than one avocado per day to avoid unwanted weight gain.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
28 minutes ago
- Medscape
Loneliness Among US Adults: A Growing Concern?
Approximately 37% of US adults experienced moderate-to-severe loneliness in a survey, with disparities by age, income, and sexual orientation. Adults who identified as gay or lesbian, those with a short sleep duration, and those who experienced depression had higher odds of experiencing loneliness. METHODOLOGY: Researchers conducted a secondary analysis of the 2021-2022 Health Information National Trends Survey-6 to assess the prevalence of loneliness in US adults and the sociodemographic, contextual, and health-related factors associated with it. The survey included data of 6252 participants, 93.6% of whom completed the loneliness module. The analytical sample comprised 5357 observations. Loneliness was measured using a four-item module that indirectly asked about the frequency of loneliness states without referencing a specific timeframe; higher scores indicated a greater frequency of self-perceived loneliness. A piecewise linear spline model and a common sense test were used to classify loneliness states, ranging from no loneliness to severe loneliness. TAKEAWAY: In 2022, 23.5% of US adults experienced moderate loneliness, whereas 14.0% faced severe loneliness; 37.4% of adults experienced moderate-to-severe loneliness. Younger adults (age, 18-34 years), individuals with lower income, those who were single or never married, and those who identified as gay or lesbian had a point prevalence of severe loneliness that was at least five points higher than the overall average. Almost a quarter of respondents with three or more comorbid conditions reported experiencing severe loneliness. The most common chronic health conditions in this group included heart conditions, lung disease, and depression. Identifying as gay or lesbian, being divorced or single, having a short sleep duration, and experiencing depression were factors independently associated with higher odds of moderate-to-severe loneliness, in a fully adjusted model. IN PRACTICE: 'While the findings presented are not intended to be definitive but somewhat exploratory, they should be considered to shed light on the content and direction for policymakers, healthcare professionals, and researchers when developing programs to address loneliness and its associated health risks. This study provides evidence to spark a discussion on the need to refine preventive health screening methods to better address loneliness and reassess the significance of moderate-to-severe loneliness as a public health threat among US adults,' the authors wrote. SOURCE: This study was led by Juan Rafael Albertorio-Diaz, MA, of Walden University in Minneapolis. It was published online on June 10, 2025, in American Journal of Preventive Medicine . LIMITATIONS: This study used self-reported data, which might have introduced recall or social desirability bias. The COVID-19 pandemic could have affected loneliness levels, making it difficult to interpret the results. Using a short-form scale to measure loneliness might have caused measurement bias. DISCLOSURES: No financial disclosures were reported by the authors. The authors declared having no conflicts of interest.
WIRED
35 minutes ago
- WIRED
A New Obesity Pill May Burn Fat Without Suppressing Appetite
Jun 16, 2025 5:00 AM An investigational drug developed by Eolo Pharma is showing promise in animal experiments and an early human trial. It could eventually be an alternative or add-on to popular GLP-1 medications. An experimental obesity pill that works in a different way from the wildly popular Ozempic may help people lose weight, according to results from a small, preliminary human trial. Ozempic and other GLP-1 drugs reduce food intake by stimulating a feeling of fullness. They act on the brain to promote satiety and on the gut to slow the movement of food through the stomach, helping people feel full longer. As a result, people on the drugs lose weight because they eat less. But a new drug may be able to burn energy, and thus fat, without reducing appetite. In a Phase I trial described today in the journal Nature Metabolism, the drug led to statistically significant weight loss in participants after two weeks. Dubbed SANA, the drug is derived from salicylate, a compound used to make aspirin. Developed by Eolo Pharma of Montevideo, Uruguay, it activates a pathway called creatine-dependent thermogenesis. Creatine is perhaps best known as a nutritional supplement taken after exercise to help build muscle mass, but the compound also occurs naturally in the human body and is important for energy production. 'It has been known for a long time that creatine has good effects on metabolism,' says Carlos Escande, cofounder and chief scientific officer of Eolo. In the 1970s, researchers found that rats exposed to cold used a lot of creatine. It wasn't until a decade ago that a Harvard team found that creatine is used in fatty adipose tissue during exposure to cold to generate heat. The process of burning energy and generating heat to maintain a stable internal temperature is known as thermogenesis. Creatine-dependent thermogenesis refers to how the breaking down of creatine, particularly in fat cells, contributes to this heat and energy production. 'What we have found is that our compound stimulates this creatine-dependent heat production pathway,' Escande says. In the first part of the trial, Eolo scientists randomly assigned 17 healthy-weight individuals to receive either a placebo or a single pill of SANA at a low, medium, or high dose. At all doses, the drug was safe and well-tolerated with no serious side effects. In the second part of the trial, they tested the drug in 24 participants with obesity for 15 days. Volunteers were randomly sorted into three groups to receive either a placebo or a low, medium, or high dose of SANA twice a day for the length of the study. Each group had six people taking the drug and two on a placebo. During the study period, participants stayed at a clinical facility where they received high-carbohydrate meals. At the end of the two weeks, the participants taking the highest dose of SANA showed weight loss of about 3 percent, which is comparable to the weight loss seen in people taking Ozempic and Wegovy over the same period of treatment. They were also asked to fill out a questionnaire regarding appetite and satiety, and none reported decreased appetite or satiety. While injected GLP-1 drugs are incredibly effective at spurring weight loss, they also come with some downsides. There can be gastrointestinal side effects and loss of muscle mass. The drugs are also expensive, at $1,000 a month or more in the US before insurance. Drug companies are interested in developing anti-obesity pills because of their relatively cheap cost to manufacture compared to injectables, and the fact that some patients would prefer to take a pill. 'There's still an unmet clinical need, and that's where Eolo wants to help,' says María Pía Garat the company's CEO. Eolo didn't exactly set out to make a weight-loss pill. Researchers at the company were originally trying to develop a drug to target inflammation, especially the kind that occurs in obesity and type 2 diabetes. But when they started testing their experimental drug in mice, it not only improved inflammation but also led to a reduction in body weight while they were on a high-fat diet. They have performed experiments out to nine months and found that the mice eventually dropped to their starting weight even while they were still eating the same, high-fat diet. In mice, SANA also preserved lean muscle mass. MRI scans show that mice treated with SANA had a greater percentage of lean body mass compared to controls, despite substantial fat loss. 'We've had stimulants before to try to increase your caloric output,' says Hans Schmidt, chief of bariatric surgery and co-director for the Center for Weight Loss and Metabolic Health at Hackensack University Medical Center, who wasn't involved in the study. One of those was the drug combination fenfluramine-phentermine, known as fen-phen, which was sold in the 1990s for weight loss but was taken off the market for causing heart damage. 'Those work on overall metabolism. They make you jittery, make you energized. This seems to work specifically at a cellular level on your fat cells,' he says. Of course, Eolo's study was very small, and the drug will need to be tested in more people to better understand its effects. The company is planning a Phase II trial later this year that will include around 100 participants with obesity and follow them for 12 weeks. They hope to conduct that trial in the United States. Garat thinks Eolo's drug could eventually be used as a stand-alone approach or in combination with GLP-1 drugs to produce more weight loss. 'Right now we are bringing a backhoe to the construction site when we need many more tools. We need more mechanisms like this that work on pathways other than appetite,' says Angela Fitch, former president of the Obesity Medicine Association and the cofounder and chief medical officer of Knownwell, a primary care company specializing in obesity care. Fitch is not involved with Eolo. Current GLP-1s can achieve up to 20 percent weight loss, and while that may be enough for some patients, others may still need to lose more to get to a healthy weight. 'New medications,' she says, 'present the opportunity to make an even greater impact.'
Fast Company
36 minutes ago
- Fast Company
5 signals that make you instantly more trustworthy at work
Believe it or not, first impressions are biological. When meeting someone for the first time, well before your résumé or title is considered, your brain and body are sending and receiving subtle signals that influence trust. In today's workplaces, where hybrid teams and digital interactions dominate, those signals matter more than ever. The good news is that you can learn to send them more intentionally. In my work developing Leadership Biodynamics, a biology of behavior approach to executive presence, I help leaders become more aware of how trust and connection are built at the behavioral level. The signals that trigger trust are not abstract: they're cues the human brain is wired to read quickly and deeply, because in evolutionary terms, deciding whether someone was safe to approach was once a matter of survival. That's still true in the modern workplace. Whether you're onboarding to a new team, pitching an idea to executives, or building rapport with clients, the signals you send, especially those of warmth, create the foundation for influence. Here are five warmth signals, rooted in behavioral science, that can make you instantly more trustworthy at work. 1. Listen With Full Attention In any conversation, your body gives away whether you are truly listening. Direct eye contact, open posture, leaning slightly forward, and subtle nods all signal active attention. These cues calm the other person's limbic system, reducing social threat and increasing openness. Research on neuroception, the brain's unconscious scanning for cues of safety, shows that listening behaviors have an outsized impact on trust. When someone perceives you as fully present, they are more likely to see you as trustworthy. 2. Acknowledge and Validate Others Warmth is not just about being friendly. It's about making others feel seen and valued. Small behaviors, such as verbally acknowledging good work, validating concerns, or thanking colleagues meaningfully, send powerful signals. In Leadership Biodynamics, I teach that validation is a key biological mechanism of social bonding. When you acknowledge another's contribution, you activate neural circuits linked to oxytocin release. This reinforces affiliation and trust. 3. Focus On Others In Conversation It's easy to let a conversation drift back to your own experiences or ideas. However, warmth signals are amplified when you keep the focus on the other person. Ask questions. Draw them out. Let them shine. Behavioral science research supports this. Studies show that people rate conversations more positively when the other person shows genuine interest and curiosity about them. This behavior is linked to increased perceptions of trustworthiness and likability. 4. Be Approachable and Easy To Relate To Approachability is a behavioral signal with deep biological roots. From a neuroscience perspective, a smiling face, relaxed tone of voice, and nonthreatening posture lower others' cortisol responses and increase approach behaviors. Even small shifts in physical demeanor can change how others regulate their own behavior in response to you. Warmth cues such as smiling when greeting colleagues or using humor appropriately make you easier to approach. As a result, you are more trusted. 5. Show Thoughtfulness In Small Actions Trust is cumulative. Seemingly minor actions, like following up after a conversation, remembering a colleague's birthday, or offering help without being asked, signal consistency and care over time. Behavioral scientists have shown that such acts trigger reciprocal altruism mechanisms in the brain. This strengthens relational bonds. In leadership terms, they contribute to what I call a positive relational 'microclimate,' a state in which trust, loyalty, and collaboration flourish. Why These Signals Matter Now In hybrid workplaces, where informal trust-building moments are fewer, warmth signals become even more important. They help compensate for the missing relational glue that office proximity once provided. The latest research on team trust and psychological safety confirms this. Teams that build trust quickly perform better, especially under uncertainty. Warmth signals are often the fastest path to that trust. It is not status or credentials, but behavioral cues that others can feel in the moment. Trust is not built by charisma. It is built by signals your biology already knows how to send. The opportunity is to send them more intentionally. The bottom line is this: if you want to become more trustworthy at work, start small. Tune your warmth signals. Listen fully, validate openly, focus on others, be approachable, and act thoughtfully. In the biology of behavior, these are the cues that connect. And connection is what drives trust and influence.
